Rebecca Y. Linfield
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rebecca Y. Linfield has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Leon S. Moskatel
Department of Neurology Stanford University Palo Alto California USA
3 shared publications - David Jason Gershkoff Slusky
Department of Economics, University of Kansas, Lawrence, Kansas, USA
2 shared publications - Julie Parsonnet
Departments of Medicine and of Epidemiology and Population Health, Stanford University, Stanford, CA, USA
2 shared publications - Aarthi Chary
Stanford University School of Medicine, Stanford, CA, USA
1 shared publication Alessandro Zulli
Department of Civil and Environmental Engineering, Stanford University, Stanford, USA
1 shared publication- Alexandria Bianca Boehm
Department of Civil and Environmental Engineering, Stanford University, Stanford, CA, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Wastewater surveillance reveals patterns of antibiotic resistance across the United States
Antibiotic resistance is a growing public health threat, with over 2.8 million antibiotic-resistant infections and 35,000 attributable deaths annually in the U.S. Here, we sought to use wastewater monitoring to assess community-level burden of antibiotic resistance. This study quantifies concentrations of antibiotic resistance genes (ARGs) by digital droplet PCR in wastewater solids obtained from 163 wastewater treatment plants in 40 states in the United States. We measure 11 ARGs that confer resistance to beta-lactams ( bla CMY , bla CTX-M , bla KPC , bla NDM , bla OXA-48 , bla TEM , bla VIM ), colistin ( mcr-1 ), methicillin ( mecA ), tetracycline ( tetW ), and vancomycin ( vanA ). The South has higher overall ARG concentrations compared to the Midwest. We pair these data with national data sets including antibiotic use, social vulnerability, size of animal agriculture operations, location of healthcare facilities, and presence of airports to investigate potential drivers of resistance. We also generate predictive maps of ARG concentrations for counties with data within the range of our training set in the United States. We show social vulnerability indicators (housing burden and access to health insurance) and indicators of international travel are associated with increased ARG concentrations in wastewater, while antibiotic usage is only weakly positively associated. Our results provide a national baseline of ARG concentrations and highlight the complexity of factors driving spread of antibiotic resistance.
- 1 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessWastewater surveillance reveals patterns of antibiotic resistance across the United States
Antibiotic resistance is a growing public health threat, with over 2.8 million antibiotic-resistant infections and 35,000 attributable deaths annually in the U.S. Here, we sought to use wastewater monitoring to assess community-level burden of antibiotic resistance. This study quantifies concentrations of antibiotic resistance genes (ARGs) by digital droplet PCR in wastewater solids obtained from 163 wastewater treatment plants in 40 states in the United States. We measure 11 ARGs that confer resistance to beta-lactams ( bla CMY , bla CTX-M , bla KPC , bla NDM , bla OXA-48 , bla TEM , bla VIM ), colistin ( mcr-1 ), methicillin ( mecA ), tetracycline ( tetW ), and vancomycin ( vanA ). The South has higher overall ARG concentrations compared to the Midwest. We pair these data with national data sets including antibiotic use, social vulnerability, size of animal agriculture operations, location of healthcare facilities, and presence of airports to investigate potential drivers of resistance. We also generate predictive maps of ARG concentrations for counties with data within the range of our training set in the United States. We show social vulnerability indicators (housing burden and access to health insurance) and indicators of international travel are associated with increased ARG concentrations in wastewater, while antibiotic usage is only weakly positively associated. Our results provide a national baseline of ARG concentrations and highlight the complexity of factors driving spread of antibiotic resistance.
- 18 December 2025
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 53 (5) , 333-334
The Association of Mpox Incidence and Vaccination With Bacterial Sexually Transmitted Infections Incidence in Men
Utilizing aggregated, US electronic medical record data at the state level, we found that increased mpox incidence was associated with increased bacterial sexually transmitted infection (STI) rates in men for the same month and higher STI rates after the second mpox vaccination. Those seeking vaccination or testing for mpox should be screened for other STIs.
- 18 December 2025
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 53 (5) , 333-334
The Association of Mpox Incidence and Vaccination With Bacterial Sexually Transmitted Infections Incidence in Men
Utilizing aggregated, US electronic medical record data at the state level, we found that increased mpox incidence was associated with increased bacterial sexually transmitted infection (STI) rates in men for the same month and higher STI rates after the second mpox vaccination. Those seeking vaccination or testing for mpox should be screened for other STIs.
- Open Access
- 10 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Use of Intrathecal Amphotericin for Coccidioidal Meningitis
Background: Cases of coccidioidomycosis are increasing dramatically in the U.S. The utility of intrathecal (IT) amphotericin in treating coccidioidal meningitis (CM) in the era of azole therapy is unknown. We sought to understand how IT therapy is associated with mortality. Methods: We conducted a retrospective chart review of adult patients with laboratory-proven CM seen at Stanford Healthcare by an Infectious Diseases physician from 2008-2023. Results: 57 patients met inclusion criteria. All patients received azole therapy. Twenty-seven of those patients (47.4%) additionally received IT amphotericin. Patients receiving IT therapy had had a higher median initial CSF WBC at diagnosis (462.5 vs. 188, p = 0.05), higher rates of IV liposomal amphotericin use (88.9% vs. 56.7%, p = 0.02) and corticosteroid use (51.9% vs. 26.7%, p = 0.09), and higher median therapeutic switches per year (0.84 vs. 0.44, p = 0.01). An unadjusted Kaplan-Meier curve demonstrated a five-year mortality rate of 26.7% in the IT amphotericin group, compared to 6.7% in non-receiver group, p = 0.28. A Cox regression revealed that older age at diagnosis (HR 1.07, 95% CI 1.03-1.11), receipt of IT amphotericin (HR 13.9, 95% CI 1.93-100.48), and corticosteroid use (HR 8.3, 95% CI 1.92-35.4) were significantly associated with mortality, with a significant interaction between IT amphotericin and corticosteroids (interaction HR 0.14, 95% CI 0.02-0.97). Conclusions: Patients who received IT amphotericin had higher mortality rates than those who did not, likely reflecting disease refractory to treatment. More therapies are needed for those who have disease progression on azole therapy.
- 10 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Open AccessUse of Intrathecal Amphotericin for Coccidioidal Meningitis
Background: Cases of coccidioidomycosis are increasing dramatically in the U.S. The utility of intrathecal (IT) amphotericin in treating coccidioidal meningitis (CM) in the era of azole therapy is unknown. We sought to understand how IT therapy is associated with mortality. Methods: We conducted a retrospective chart review of adult patients with laboratory-proven CM seen at Stanford Healthcare by an Infectious Diseases physician from 2008-2023. Results: 57 patients met inclusion criteria. All patients received azole therapy. Twenty-seven of those patients (47.4%) additionally received IT amphotericin. Patients receiving IT therapy had had a higher median initial CSF WBC at diagnosis (462.5 vs. 188, p = 0.05), higher rates of IV liposomal amphotericin use (88.9% vs. 56.7%, p = 0.02) and corticosteroid use (51.9% vs. 26.7%, p = 0.09), and higher median therapeutic switches per year (0.84 vs. 0.44, p = 0.01). An unadjusted Kaplan-Meier curve demonstrated a five-year mortality rate of 26.7% in the IT amphotericin group, compared to 6.7% in non-receiver group, p = 0.28. A Cox regression revealed that older age at diagnosis (HR 1.07, 95% CI 1.03-1.11), receipt of IT amphotericin (HR 13.9, 95% CI 1.93-100.48), and corticosteroid use (HR 8.3, 95% CI 1.92-35.4) were significantly associated with mortality, with a significant interaction between IT amphotericin and corticosteroids (interaction HR 0.14, 95% CI 0.02-0.97). Conclusions: Patients who received IT amphotericin had higher mortality rates than those who did not, likely reflecting disease refractory to treatment. More therapies are needed for those who have disease progression on azole therapy.
- 18 July 2025
- Published by Wiley in Journal of Hospital Medicine
- Vol. 20 (12) , 1377-1382
The impact of a best practice advisory for shifting to oral medications: A quality improvement project
We developed a Best Practice Advisory (BPA) to encourage switching from intravenous (IV) to oral (PO) formulations of antimicrobials with equal efficacy, to decrease costs and IV usage. We conducted a prospective study analyzing our BPA's effect on prescribing practices of antimicrobials in the inpatient setting of Stanford Hospital in Palo Alto, CA, over a 22‐month period. Our BPA achieved a 1526/6585 (23.2%) acceptance rate and led to decreased use of IV antimicrobials, with substantial direct cost savings of at least $66,976. Future efforts will focus on expanding our BPA to non‐antimicrobials given ongoing IV fluid shortages.
- 18 July 2025
- Published by Wiley in Journal of Hospital Medicine
- Vol. 20 (12) , 1377-1382
The impact of a best practice advisory for shifting to oral medications: A quality improvement project
We developed a Best Practice Advisory (BPA) to encourage switching from intravenous (IV) to oral (PO) formulations of antimicrobials with equal efficacy, to decrease costs and IV usage. We conducted a prospective study analyzing our BPA's effect on prescribing practices of antimicrobials in the inpatient setting of Stanford Hospital in Palo Alto, CA, over a 22‐month period. Our BPA achieved a 1526/6585 (23.2%) acceptance rate and led to decreased use of IV antimicrobials, with substantial direct cost savings of at least $66,976. Future efforts will focus on expanding our BPA to non‐antimicrobials given ongoing IV fluid shortages.
- 1 January 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (1) , 136-137
Red-Tape Roadblocks: How Prior Authorization Intermediaries Delay Optimal Patient Care
- 1 January 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (1) , 136-137
Red-Tape Roadblocks: How Prior Authorization Intermediaries Delay Optimal Patient Care
- 30 June 2024
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 17 (7) , 589-614
An update on drug–drug interactions in older adults living with human immunodeficiency virus (HIV)
People with HIV are living longer due to advances in antiretroviral therapy. With improved life expectancy comes an increased lifetime risk of comorbid conditions - such as cardiovascular disease and cancer - and polypharmacy. Older adults, particularly those living with HIV, are more vulnerable to drug interactions and adverse effects, resulting in negative health outcomes. Antiretrovirals are involved in many potential drug interactions with medications used to treat common comorbidities and geriatric conditions in an aging population of people with HIV. We review the mechanisms and management of significant drug-drug interactions involving antiretroviral medications and non-antiretroviral medications commonly used among older people living with HIV. The management of these interactions may require dose adjustments, medication switches to alternatives, enhanced monitoring, and considerations of patient- and disease-specific factors. Clinicians managing comorbid conditions among older people with HIV must be particularly vigilant to side effect profiles, drug-drug interactions, pill burden, and cost when optimizing treatment. To support healthier aging among people living with HIV, there is a growing need for antiretroviral stewardship, multidisciplinary care models, and advances that promote insight into the correlations between an individual, their conditions, and their medications.
- 30 June 2024
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 17 (7) , 589-614
An update on drug–drug interactions in older adults living with human immunodeficiency virus (HIV)
People with HIV are living longer due to advances in antiretroviral therapy. With improved life expectancy comes an increased lifetime risk of comorbid conditions - such as cardiovascular disease and cancer - and polypharmacy. Older adults, particularly those living with HIV, are more vulnerable to drug interactions and adverse effects, resulting in negative health outcomes. Antiretrovirals are involved in many potential drug interactions with medications used to treat common comorbidities and geriatric conditions in an aging population of people with HIV. We review the mechanisms and management of significant drug-drug interactions involving antiretroviral medications and non-antiretroviral medications commonly used among older people living with HIV. The management of these interactions may require dose adjustments, medication switches to alternatives, enhanced monitoring, and considerations of patient- and disease-specific factors. Clinicians managing comorbid conditions among older people with HIV must be particularly vigilant to side effect profiles, drug-drug interactions, pill burden, and cost when optimizing treatment. To support healthier aging among people living with HIV, there is a growing need for antiretroviral stewardship, multidisciplinary care models, and advances that promote insight into the correlations between an individual, their conditions, and their medications.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
338. ChatGPT Conveys Incorrect Information about the FDA’s Antibiotic Boxed Warnings
Chat Generative Pre-training Transformer (ChatGPT) is a popular artificial intelligence-based chatbot that rapidly provides responses to online inquiries. As a language-processing – rather than a scientific – tool, ChatGPT does not guarantee accuracy. The United States Food and Drug Administration (FDA) labels medications with significant risk of serious or life-threatening adverse effects with boxed warnings (BW). We sought to assess the accuracy of ChatGPT regarding FDA BW for antibiotics. (1) “Matching”: ChatGPT accurately reported both existence and content of BW or its absence; (2) “Inaccurate”: ChatGPT accurately reported a BW but erred on some aspects of the content; and (3) “Incorrect”: ChatGPT misidentified existence of BW, or listed incorrect adverse effects (AE) FDA Boxed Warnings for Commonly Used Antibiotics ChatGPT Responses about FDA Boxed Warnings Examples of Incorrect ChatGPT claims ChatGPT reported inaccurate and incorrect information about FDA BW for antibiotics. Clinicians should be aware of this new source of information for patients. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access338. ChatGPT Conveys Incorrect Information about the FDA’s Antibiotic Boxed Warnings
Chat Generative Pre-training Transformer (ChatGPT) is a popular artificial intelligence-based chatbot that rapidly provides responses to online inquiries. As a language-processing – rather than a scientific – tool, ChatGPT does not guarantee accuracy. The United States Food and Drug Administration (FDA) labels medications with significant risk of serious or life-threatening adverse effects with boxed warnings (BW). We sought to assess the accuracy of ChatGPT regarding FDA BW for antibiotics. (1) “Matching”: ChatGPT accurately reported both existence and content of BW or its absence; (2) “Inaccurate”: ChatGPT accurately reported a BW but erred on some aspects of the content; and (3) “Incorrect”: ChatGPT misidentified existence of BW, or listed incorrect adverse effects (AE) FDA Boxed Warnings for Commonly Used Antibiotics ChatGPT Responses about FDA Boxed Warnings Examples of Incorrect ChatGPT claims ChatGPT reported inaccurate and incorrect information about FDA BW for antibiotics. Clinicians should be aware of this new source of information for patients. All Authors: No reported disclosures
- 7 November 2022
- Published by Springer Nature in AIDS and Behavior
- Vol. 27 (5) , 1647-1652
The 1982 Medicaid Funding Cessation for Circumcision in California and Circumcision Rates
We investigated California’s 1982 decision to stop funding Medicaid neonatal circumcision. We examined male neonatal circumcision rates for those born 1977–1981 and 1983–1987 by region, race, and insurance status. Overall, West-Medicaid circumcision rates decreased from 56.5% in 1979-81 to 26.7% in 1983-85. California’s 1982 decision to defund Medicaid circumcision coverage was associated with a 25.0-30.8% point decrease in West-Medicaid circumcision rates compared other groups, p < 0.01. This provides the earliest data to support that funding coverage for neonatal circumcision affects circumcision rates and magnifies healthcare disparities. Other states have since defunded Medicaid male neonatal circumcision. Circumcision have been associated with lower rates of sexually transmitted infections including HIV, and urinary tract infections. Lawmakers should consider re-funding Medicaid male neonatal circumcision.
- 7 November 2022
- Published by Springer Nature in AIDS and Behavior
- Vol. 27 (5) , 1647-1652
The 1982 Medicaid Funding Cessation for Circumcision in California and Circumcision Rates
We investigated California’s 1982 decision to stop funding Medicaid neonatal circumcision. We examined male neonatal circumcision rates for those born 1977–1981 and 1983–1987 by region, race, and insurance status. Overall, West-Medicaid circumcision rates decreased from 56.5% in 1979-81 to 26.7% in 1983-85. California’s 1982 decision to defund Medicaid circumcision coverage was associated with a 25.0-30.8% point decrease in West-Medicaid circumcision rates compared other groups, p < 0.01. This provides the earliest data to support that funding coverage for neonatal circumcision affects circumcision rates and magnifies healthcare disparities. Other states have since defunded Medicaid male neonatal circumcision. Circumcision have been associated with lower rates of sexually transmitted infections including HIV, and urinary tract infections. Lawmakers should consider re-funding Medicaid male neonatal circumcision.